Aspira Women’s Health (NASDAQ:AWH) Receives New Coverage from Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the stock.

Separately, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $3.30 target price on shares of Aspira Women’s Health in a research note on Wednesday, April 10th.

Aspira Women’s Health Trading Down 33.6 %

Aspira Women’s Health stock opened at $0.99 on Tuesday. Aspira Women’s Health has a 12 month low of $0.90 and a 12 month high of $6.75. The stock’s 50 day simple moving average is $2.39 and its two-hundred day simple moving average is $3.42. The firm has a market cap of $12.33 million, a PE ratio of -0.68 and a beta of 1.54.

Aspira Women’s Health (NASDAQ:AWH) last announced its earnings results on Tuesday, May 21st. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). The firm had revenue of $2.15 million during the quarter, compared to analysts’ expectations of $2.10 million. During the same quarter last year, the business earned ($10.94) EPS. On average, equities research analysts forecast that Aspira Women’s Health will post -1.3 EPS for the current year.

Hedge Funds Weigh In On Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. Quantum Private Wealth LLC raised its position in Aspira Women’s Health Inc. (NASDAQ:AWH) by 76.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,156 shares of the company’s stock after acquiring an additional 21,788 shares during the quarter. Quantum Private Wealth LLC owned approximately 0.49% of Aspira Women’s Health worth $205,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.